Clinical Trial Update: Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update indicating that chronic hepatitis B patients who lose HBeAg may maintain a sustained off-treatment response after stopping nucleos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• nucleos(t)ide analogues

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Hepatitis B | Phase 4 | Status: UNKNOWN